Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-term Study of JTE-061 Cream in Atopic Dermatitis
jRCT2031210256Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tapinarof in atopic dermatitis (AD), sponsored by Japan Tobacco. Primary endpoints: Safety: adverse events and adverse drug reactions, Safety: laboratory test abnormalities and 1 more. Started Sep 2021; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031210256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210256.